Results 121 to 130 of about 9,892 (240)

Tolvaptan, a Selective Oral Vasopressin V2 -Receptor Antagonist, for Hyponatremia [PDF]

, 2018
Berl, Tomas, Czerwiec, Frank S., Gheorghiade, Mihai, Gross, Peter, Nagy, Endre V., Orlandi, Cesare, Schrier, Robert W., Verbalis, Joseph G.   +7 more
core   +1 more source

Ваптаны в лечении хронической сердечной недостаточности (ХСН) [PDF]

, 2013
Анализ научной медицинской литературы, содержащей информацию о новом классе препаратов "ваптаны" в терапии ...
Ефремова, О. А., Железнова, Е. А., Коррейа, Л. Л.   +2 more
core  

Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites

, 2019
Eri Sagawa, Hironao Okubo, Hitoshi Ando, Yushi Sorin, Ryo Kanazawa, Eisuke Nakadera, Hiroo Fukada, Shigehiro Kokubu, Akihisa Miyazaki   +8 more
openalex   +1 more source

SP013EFFICACY OF TOLVAPTAN ON AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) PATIENTS IN LATE-STAGE CKD [PDF]

, 2017
Fumihiko Hattanda, Minoru Makita, Sayo Takeda, Kanako Watanabe, Keisuke Kawashima, Keiichi Kondo, Yozou Ishikawa, Yoshihiro Kusunoki, Yasunobu Ishikawa, Saori Nishio, Tatsuya Atsumi   +10 more
openalex   +1 more source

Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. [PDF]

, 2018
Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 ...
Bourgeois, Bryan C, Kruger, Samantha L, Shillingford, Jonathan M, Torres, Jacob, Weimbs, Thomas   +4 more
core   +1 more source

#510 Evaluating tolvaptan as a protective agent for cardiac insufficiency in peritoneal dialysis patients [PDF]

Theodora Oikonomaki
openalex   +1 more source

Case report of domiciliary treatment with Tolvaptan in patients with advanced heart failure and persistent hyponatremia [PDF]

, 2015

openalex   +1 more source

Tolvaptan, a vasopressin V₂ receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)

, 2021
Yoshihisa Yamada, Hiroyuki Fujiki, Hiroshi Mizuguchi, Yukinobu Takeshita, Katsuji Hattori, Koji Ohmoto, Miki Aihara, Keisuke Nagano, Yoshitaka Yamamura   +8 more
openalex   +2 more sources

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. [PDF]

, 2017
Peters, S., Rizvi, N.A.
core   +1 more source

Daily Monitoring of Serum <i>Wisteria floribunda</i> Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites

, 2020
Masaaki Takamura, Akira Sakamaki, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai   +8 more
openalex   +2 more sources